Vaccinating humans to protect mosquitoes from malaria

October 9, 2018 by Cory Nealon, University at Buffalo
Anopheles gambiae mosquito, feeding on blood. Credit: James Gathany, Centers for Disease Control and Prevention

For decades, scientists have been trying to develop a vaccine that prevents mosquitoes from spreading malaria among humans.

This unique approach—in which immunized humans transfer anti-malarial proteins to when bitten—is called a transmission-blocking (TBV). A few malarial TBVs have shown promise but they have not been widely tested due to unwanted side effects or limited effectiveness.

That could change.

A biotechnology advancement reported Monday, Oct. 8, in the journal Nature Nanotechnology describes how a University at Buffalo-led research team has devised a simple way to boost the efficacy of malarial TBVs.

If successful, it could help reduce the spread of the disease, which kills more than 400,000 people annually, mostly small children in sub-Saharan Africa.

"Malaria is a huge global problem. This approach—using a transmission-blocking vaccine—could be part of a suite of tools that we use to tackle the disease," says the study's lead author, Jonathan Lovell, PhD, associate professor of biomedical engineering, a joint program of UB's School of Engineering and Applied Sciences and the Jacobs School of Medicine and Biomedical Sciences at UB.

Co-authors include researchers from Walter Reed Army Institute of Research, the National Institutes of Health, McGill University and the PATH Malaria Vaccine Initiative.

How malaria is spread

Utilizing TBVs to fight stems, in part, from how the disease is spread. Here is how it works: a mosquito carrying the disease bites a child and transmits the malaria parasite to her. Later, a non-infected mosquito bites the child, and this time it's the girl who passes the parasite to the mosquito. That mosquito later bites a new victim and infects them with the parasite.

The development of effective TBVs—combined with bug nets, insecticides, anti-parasitic drugs and others types of vaccines—could help break this vicious cycle, proponents say. While a TBV would not directly prevent an immunized person from getting infected, the vaccine would reduce the odds that people living in that community get malaria, hopefully to zero.

Prior research in this area has focused on techniques like genetic engineering and chemical binding of toxin proteins to boost TBV responses. Each strategy has potential, but they're also time- and resource-consuming. The biotechnology created by the UB-led research team differs in its relative ease of assemble and overall effectiveness, Lovell says.

The 's life cycle includes numerous stages. Different malaria proteins represent the best vaccine target antigens, which are proteins that a vaccine mounts an immune response against. To purify these antigens for a vaccine, they are often modified with a small chain of amino acids called a polyhistidine-tag.

The research team's discovery

Researchers discovered that the antigens could be mixed with nanoparticles containing small amounts of cobalt-porphyrin and phospholipid. The cobalt-porphyrin, which is similar in structure to vitamin B12, is responsible for binding the nanoparticle to the antigens.

The resulting structure is a next-generation adjuvant, which is an immunological agent that enhances the efficacy of vaccines. The vaccine works by inducing humans to make malaria-attacking antibodies, which are then transmitted to the mosquito as it bites the immunized human.

In tests involving mice and rabbits, researchers showed that antibodies from a protein called Pfs25 effectively blocked the development of malaria-causing parasites inside the gut of mosquitoes. Additional tests paired the adjuvant with multiple malaria antigens, suggesting its promise for blocking the spread of malaria at numerous stages of the disease.

The research team's next step is to prepare additional experiments that will justify moving the technology into human trials.

Explore further: Combining different malaria vaccines could reduce cases by 91 percent

More information: Wei-Chiao Huang et al. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes, Nature Nanotechnology (2018). DOI: 10.1038/s41565-018-0271-3

Related Stories

Human antibodies undermine parasite sex

February 8, 2018

Some people develop an immune response following a malaria infection that stops them from infecting other mosquitoes. The antibodies that these people produce are ingested by the mosquito and destroy the malaria parasite ...

Study explores new strategy to develop a malaria vaccine

April 11, 2018

A serum developed by Yale researchers reduces infection from malaria in mice, according to a new study. It works by attacking a protein in the saliva of the mosquitos infected with the malaria parasite rather than the parasite ...

Researchers identify target for novel malaria vaccine

July 13, 2018

A Yale-led team of researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites ...

A promising new tool to measure antibodies against malaria

July 4, 2018

Antibodies against multiple Plasmodium falciparum proteins (or antigens) can be measured using a simple, accurate and reproducible assay that requires very small amounts of blood. In a series of recently published articles, ...

Recommended for you

Taking steps toward a wearable artificial kidney

October 17, 2018

There just aren't enough kidney transplants available for the millions of people with renal failure. Aside from a transplant, the only alternative for patients is to undergo regular dialysis sessions to clear harmful cellular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.